Drug intelligence / Profile preview

NK-102

Development stage: Unknown
Lead developer: Neurokin
Administration: Intravenous

Overview

NK-102 is a neuroprotective drug under development by the French biotech company NEUROKIN. It is being advanced for the treatment of stroke, an area with high unmet medical need. The development is supported by a grant from the Agence Nationale de la Recherche (ANR) as part of the STROKININ project, which aims to deepen preclinical proof of concept and prepare for Phase II clinical trials.

Beyond the preview

Go deeper on NK-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK-102.

Explore the full profile